Skip to main content

Healthy Adult Participants

13
Pipeline Programs
14
Companies
20
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
12
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 16 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

RIGImmune
RIGImmuneCT - Farmington
1 program
1
RIG-101Phase 1/21 trial
Active Trials
NCT07488897Recruiting82Est. Feb 2027
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
3
ALXN2230Phase 1
Gefurulimab PFS-SDPhase 11 trial
Treatment APhase 15 trials
Active Trials
NCT06208488Completed175Est. Sep 2024
NCT05578846Completed42Est. Jan 2023
NCT04768985Completed66Est. May 2021
+3 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
2
Oral [14C] PF-07248144Phase 11 trial
PF-07248144Phase 11 trial
Active Trials
NCT07423286Completed8Est. Jan 2026
NCT07335419Active Not Recruiting12Est. Mar 2026
ADARx Pharmaceuticals
ADARx PharmaceuticalsCA - San Diego
1 program
1
ADX-626Phase 11 trial
Active Trials
NCT07081503Recruiting44Est. Jan 2027
Biocad
BiocadRussia - St. Petersburg
1 program
1
BCD-261Phase 11 trial
Active Trials
NCT07535775Not Yet Recruiting48Est. Mar 2027
Otsuka
OtsukaJapan - Tokushima
1 program
1
CentanafadinePhase 11 trial
Active Trials
NCT07486895Completed44Est. May 2023
Dong-A ST
Dong-A STKorea - Seoul
1 program
1
DA-5230Phase 11 trial
Active Trials
NCT07513649Not Yet Recruiting60Est. May 2026
Chengdu Kanghong Pharmaceutical Group
1
KHN707 tabletPhase 11 trial
Active Trials
NCT07557537Not Yet Recruiting38Est. Oct 2026
Mediar Therapeutics
1 program
1
MTX-439Phase 11 trial
Active Trials
NCT07473323Not Yet Recruiting88Est. Jan 2028
Servier
ServierFrance - Suresnes
1 program
1
VorasidenibPhase 1Small Molecule1 trial
Active Trials
NCT07235748Completed28Est. Dec 2025
Parexel
ParexelMA - Boston
2 programs
Gefurulimab PFS-SDPHASE_1
Treatment APHASE_1
Edgewise Therapeutics
1 program
EDG-7500PHASE_11 trial
Active Trials
NCT07456059Not Yet Recruiting24Est. Jun 2026
mAbxience
mAbxienceSwitzerland - Lugano
1 program
PalivizumabPHASE_1Monoclonal Antibody1 trial
Active Trials
NCT04540627Completed56Est. Oct 2020
Takeda
TakedaTOKYO, Japan
1 program
VortioxetinePHASE_11 trial
Active Trials
NCT03437564Completed28Est. Apr 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaTreatment A
RIGImmuneRIG-101
BiocadBCD-261
Mediar TherapeuticsMTX-439
Chengdu Kanghong Pharmaceutical GroupKHN707 tablet
Dong-A STDA-5230
Edgewise TherapeuticsEDG-7500
PfizerPF-07248144
PfizerOral [14C] PF-07248144
ServierVorasidenib
ADARx PharmaceuticalsADX-626
AstraZenecaGefurulimab PFS-SD
OtsukaCentanafadine
AstraZenecaTreatment A
AstraZenecaTreatment A

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 1,267 patients across 20 trials

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Start: Oct 2006Est. completion: Jan 2009252 patients
Phase 4Completed

RIG 101 Trial in Healthy Adults and Adults With Asthma

Start: Feb 2026Est. completion: Feb 202782 patients
Phase 1/2Recruiting

Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers

Start: May 2026Est. completion: Mar 202748 patients
Phase 1Not Yet Recruiting

Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

Start: May 2026Est. completion: Jan 202888 patients
Phase 1Not Yet Recruiting

A Phase 1 Study of KHN707 Tablets in Healthy Participants

Start: May 2026Est. completion: Oct 202638 patients
Phase 1Not Yet Recruiting

A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R

Start: Apr 2026Est. completion: May 202660 patients
Phase 1Not Yet Recruiting

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

Start: Mar 2026Est. completion: Jun 202624 patients
Phase 1Not Yet Recruiting

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

Start: Jan 2026Est. completion: Mar 202612 patients
Phase 1Active Not Recruiting
NCT07423286PfizerOral [14C] PF-07248144

A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

Start: Oct 2025Est. completion: Jan 20268 patients
Phase 1Completed

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Start: Oct 2025Est. completion: Dec 202528 patients
Phase 1Completed

Phase 1 Study of ADX-626 in Healthy Participants

Start: Aug 2025Est. completion: Jan 202744 patients
Phase 1Recruiting
NCT06208488AstraZenecaGefurulimab PFS-SD

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Start: Nov 2023Est. completion: Sep 2024175 patients
Phase 1Completed
NCT07486895OtsukaCentanafadine

Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

Start: Mar 2023Est. completion: May 202344 patients
Phase 1Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Start: Oct 2022Est. completion: Jan 202342 patients
Phase 1Completed

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Start: Feb 2021Est. completion: May 202166 patients
Phase 1Completed

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

Start: Oct 2020Est. completion: Dec 202020 patients
Phase 1Completed

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Start: Jul 2020Est. completion: Oct 202056 patients
Phase 1Completed

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Start: Sep 2018Est. completion: Oct 201824 patients
Phase 1Completed
NCT03437564TakedaVortioxetine

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Start: Feb 2018Est. completion: Apr 201828 patients
Phase 1Completed

A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)

Start: Jul 2007Est. completion: Apr 2008128 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,267 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.